Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia

Clinical Laboratory

Volumn 60, Issue 10, 2014, Pages 1601-1607

  Wand, Saskia ^a,b   Baro, Daniel ^a   Baecker, Christina ^c   Meybohm, Patrick ^a   Schmitz Rixen, Thomas ^a   Zacharowski, Kai ^a   Mutlak, Haitham ^a   Weber, Christian Friedrich ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c Kerckhoff Heart and Thorax Centre   (Germany)

Author keywords

Dual antiplatelet therapy; Multiple electrode aggregometry; Peripheral artery occlusive disease

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALANINE AMINOTRANSFERASE; ARACHIDONIC ACID; ASPARTATE AMINOTRANSFERASE; CLOPIDOGREL; FIBRINOGEN; GLUTAMATE DEHYDROGENASE; HEMOGLOBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

AGED; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; CRITICAL LIMB ISCHEMIA; EX VIVO STUDY; FEMALE; HEMATOCRIT; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PROSPECTIVE STUDY; PROTHROMBIN TIME; REVASCULARIZATION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION ANALYZER; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; CRITICAL ILLNESS; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; GERMANY; ISCHEMIA; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; ASPIRIN; CRITICAL ILLNESS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84908424009     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2013.131007     Document Type: Article

References (32)

1. Thorn T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:85-151.
2. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24.
3. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from SUMS, the Swedish Ticlopidi-ne Multicentre Study. J Intern Med 1990;227:301-8.
4. Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:609-26.
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
6. Bhatt DL, Fiather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982-8.
7. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336:195-8.
8. Sofi F, Marcucci R, Gori AM, et al. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events a metaanalysis. Int J Cardiol 2008;128:166-71.
9. Sofi F, Giusti B, Marcucci R, et al. Cytochrome P450 2C19∗2 polymorphism and cardiovascular recurrences in patients taking Clopidogrel: a meta-analysis. Pharmacogenomics J 2011;11:199-206.
10. Liu Y, Liu N, Li W, et al. Clopidogrel response variability and its correlation with early recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention. Pharmacology 2011;87:321-30.
11. Dietim C, Lange S, Darius H, et al. Association of low ankle brachial index with high mortality in primary care. Eur Heart J 2006; 27:1743-9.
12. Duvall WL, Vorchheimer DA. Multi-bed vascular disease and atherothrombosis: scope of the problem. J Thromb Thrombolysis 2004;17:51-61.
13. ROmenapf G, Diehm C. Periphere arterielle Verschlusskrankheit (PAVK) - Krankheitswert wird unterschätzt [Peripheral artery occlusive disease (PAOD) - disease significance is underestimated]. Deutsches Ärzteblatt 2011;108:2094-5.
14. Cardinal DC, Flower PJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980;3:135-58.
15. Weber CF, Hampp K, Zacharowski K, et al. Evaluation of Multiple Electrode Aggregometry for the perioperative assessment of aspirin therapy in cardiac surgery. Applied Cardiopulmonary Pathophysiology 2010;14:163-73.
16. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367: 606-17.
17. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309-17.
18. Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 1991;83:1526-33.
19. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007;167:1593-9.
20. Silva FB, Almeida Junior GL, Neno A, et al. Resistance to Clopidogrel: prevalence and associate variables. Arq Bras Cardiol 2012;99:1135-41.
21. Poston RS, Gu J, Brown JM, et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006;131:122-30.
22. Sibbing D, Morath T, Braun S, et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010;103:151-9.
23. Price Ml, Berger PB, Teirstein PS, et al. Standard- vs high-dose Clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105.
24. Bonello L, Camoin-Jau L, Armerò S, et al. Tailored Clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103:5-10.
25. Valgimigli M, Campo G, De Cesare N, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, Clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009; 119: 3215-22.
26. Hazarbasanov D, Velchev V, Finkov B, et al. Tailoring Clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis 2012;34:85-90.
27. Aradi D, Komocsi A, Price MJ, et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol 2013;167: 2140-8.
28. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367:2100-9.
29. Reny JL, Berdague P, Poncet A, et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation 2012;125:3201-10.
30. Voisin S, Bongard V, Tidjane MA, et al. Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the Verify Now assay? Role of haematocrit and haemoglobin levels. Thromb Haemost 2011;106:227-9.
31. Rubak P, Villadsen K, Hvas AM. Reference intervals for platelet aggregation assessed by multiple electrode platelet aggregometry. Thromb Res 2012;130:420-3.
32. Velik-Salchner C, Maier S, Innerhofer P, et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and Clopidogrel: the results of a pilot study. Anesth Analg 2008;107:1798-806.